NOW AVAILABLE: TWYNSTA Team Up to Help Control Blood Pressure is an angiotensin II receptor blocker/calcium channel blocker (ARB/CCB) that combines telmisartan—the active ingredient in Micardis® (telmisartan) Tablets—and amlodipine. Learn more about efficacy Review safety data

TWYNSTA Efficacy TWYNSTA was more effective in lowering in-clinic SBP/DBP after 8 weeks than monotherapy1* * Placebo-corrected. Primary endpoint in this study was change in the in-clinic seated trough DBP. In an 8-week, placebo-controlled, factorial design study, the 4 key treatment combinations (including combinations of telmisartan 40 or 80 mg and amlodipine 5 or 10 mg) had statistically significant reduction in in-clinic seated trough cuff systolic and diastolic blood pressure compared to the respective individual monotherapies.† Review TWYNSTA study results

The concomitant use of telmisartan and amlodipine has been evaluated for safety in more than 3700 patients with hypertension. Review TWYNSTA safety data Visit the MICARDIS for Healthcare Professionals Web site to access tools and resources designed to help you create individualized treatment plans for your hypertensive patients. Go to www.MicardisPro.com

†An 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel group factorial study in patients with mild to severe hypertension was conducted to determine if treatment with TWYNSTA was more effective in reducing blood pressure compared to the respective monotherapies. The study randomized 1461 patients with baseline systolic blood pressure between 117 and 179 mmHg (mean 153 mmHg) and baseline diastolic blood pressure between 90 and 119 mmHg (mean 102 mmHg) to 1 of the 16 treatment arms. Patients assigned to receive amlodipine 10 mg started on amlodipine 5 mg or combinations thereof for the first 2 weeks.

Reference
1. Littlejohn TW, et al. J Clin Hypertens. 2009;11:207-213.